Close monitoring of patients with systemic sclerosis-associated interstitial lung disease and awareness of the variable course of progression is highly important in considering when to initiate treatment.
Researchers evaluated the clinical characteristics and risk factors of acute exacerbations and mortality of rheumatoid arthritis-associated interstitial lung disease.
Study authors analyzed the effects of nintedanib on changes in forced vital capacity and other measures of progression in systemic sclerosis-associated interstitial lung disease.
A higher neutrophil count predicted worse disease course and higher long-term mortality in patients with systemic sclerosis-related interstitial lung disease.
Researchers characterized the safety and tolerability of nintedanib and the dose adjustments for adverse events in patients with systemic sclerosis-associated interstitial lung disease.
Researchers investigated the incidence rates of interstitial lung disease in patients with rheumatoid arthritis receiving tofacitinib and identified potential risk factors.
There are significant differences in perceptions of prevalence, risk factors, and the management of RA-associated interstitial lung disease between rheumatologists and pulmonologists.
In this systematic review, researchers assessed the role of lung ultrasound in the assessment of interstitial lung disease in systemic sclerosis.
Researchers assessed the performance of pulmonary function tests for the detection of interstitial lung disease in early diffuse cutaneous systemic sclerosis.
Researchers determined the effect of treatment with cyclophosphamide and mycophenolate mofetil on patient-reported outcomes in systemic sclerosis-related interstitial lung disease.
